

17-B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (E), Mumbai - 400 093. INDIA.
Tel. : (91-22) 6645 5645
Fax : (91-22) 6645 5685

**SUN PHARMA
ADVANCED RESEARCH
COMPANY LTD.**



August 10, 2012

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

BSE Ltd,
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001.

Dear Sirs,

Sub: Rights Issue of Sun Pharma Advanced Research Company Limited ("Company")- Notice of Book closure, Price and Ratio for entitlement of the proposed Rights Issue of the Company.

We have received observations from SEBI on our Draft Letter of Offer dated January 30, 2012, *vide* their letter dated April 25, 2012 and our Lead Manager has furnished replies to SEBI Observations *vide* letters dated June 22, 2012, July 26, 2012 and August 02, 2012. All necessary amendments/ disclosures based on the observation letter have been made in the Letter of Offer.

A brief synopsis of the Rights Issue is given below:

Meeting of the Funds Mobilising Committee of Board of Directors ("Funds Mobilising Committee")

The Funds Mobilising Committee of the Company at its meeting held today i.e. August 10, 2012, has approved the Issue price for the Rights Issue at ₹ 67 per Equity Share of ₹ 1 each.

The Issue price per share will be payable as follows:

	Payment Method		
	Amount payable per Rights Share (₹67)		
	Face Value (₹1)	Premium (₹66)	Total (₹67)
On Application	0.60	39.40	40.00
Final Call	0.40	26.60	27.00
Total	1.00	66.00	67.00

The Funds Mobilising Committee has also fixed the Book Closure Period from Saturday, August 25, 2012 to Monday, August 27, 2012 (both days inclusive) for the purpose of the Rights Issue. The Issue of Rights Shares will be made to those members of our Company, holding Equity Shares in physical form and whose names appear on our Company's Register of Members as on the close of business hours on August 24, 2012 after effecting the transfer request(s) received on or before August 24, 2012 and as

regards the members of our Company holding Equity Shares in dematerialized form, on the basis of particulars of beneficial ownership furnished by the Depositories viz., CDSL and NSDL as at the end of business hours on August 24, 2012.

Issue Size & Ratio.

Issue of 29,588,056 Equity Shares of Re. 1/- each for cash at a premium of Rs. 66/-, at a price of Rs. 67/- per share for an amount aggregating to Rs. 1,982,399,752 to its Equity Shareholders in the ratio of one (1) Equity Share of Re.1 each for every seven (7) existing Equity Shares of Re.1 each held by the Shareholders on the close of business hours on August 24, 2012.

Fractional Entitlement:

For Rights Shares being offered under the Issue, if the shareholding of any of the Equity Shareholders is less than 7 Equity Shares or is not in multiples of 7, the fractional entitlement of such Equity Shareholders shall be ignored. Equity Shareholders whose fractional entitlements are being ignored will be given preference in the allotment of one additional Rights Share each, if such Equity Shareholders have applied for any additional Rights Shares over and above their Rights Entitlement.

Those Equity Shareholders holding less than 7 Equity Shares and therefore entitled to zero Rights Shares under the Issue shall be dispatched a Composite Application Form (CAF) with zero entitlement. Such Equity Shareholders cannot renounce their entitlement to apply for additional Rights Shares in favor of any other person. Such Equity Shareholders are entitled to apply for additional Rights Shares. A CAF with zero entitlement will be non-negotiable / non renounceable.

Please treat this intimation as the 7 (seven) working days notice to fix the Record Date/ Book Closure and request you to take on record the Book Closure Period from Saturday, August 25, 2012 to Monday, August 27, 2012 (both days inclusive) for the purpose of Rights Issue and make an announcement accordingly.

Thanking you,

Yours sincerely,

For Sun Pharma Advanced Research Company Limited



Meetal S. Sampat
Company Secretary